Search clinical trials for: SUVN-G3031

Total 12 results

Suven Life Sciences Limited

Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

Cognitive Disorders

United States
Suven Life Sciences Limited

No longer available

Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy

Narcolepsy
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Cognitive Disorders

United States
Suven Life Sciences Limited

Completed

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy (SUVN-G3031)

Narcolepsy

United States, Canada
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects (SUVN-911)

Depressive Disorder, Major

United States
Suven Life Sciences Limited

Completed

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects (SUVN-911)

Major Depressive Disorder

United States
Suven Life Sciences Limited

Recruiting

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

Major Depressive Disorder

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects

Cognitive Disorder

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Cognitive Disorders

United States
Suven Life Sciences Limited

Recruiting

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Agitation | Alzheimer's Type Dementia

Croatia, United States, Poland, Serbia
Suven Life Sciences Limited

No longer available

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)

Dementia | Alzheimer Disease | Cognition Disorders
Suven Life Sciences Limited

Completed

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Alzheimer's Disease

United States

3

Subscribe